Edition:
United States

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,410JPY
26 May 2017
Change (% chg)

¥4 (+0.32%)
Prev Close
¥1,405
Open
¥1,409
Day's High
¥1,414
Day's Low
¥1,402
Volume
6,658,600
Avg. Vol
8,142,283
52-wk High
¥1,779
52-wk Low
¥1,396

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,026,122.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 18.00
Yield (%): 2.42

Financials

  4503.T Industry Sector
P/E (TTM): 13.58 14.31 17.43
EPS (TTM): 103.44 -- --
ROI: 15.58 -7.26 -5.41
ROE: 17.28 -6.76 -4.69

BRIEF- Astellas Pharma completes acquisition of Ogeda SA in Belgium

* Says it has completed the acquisition of Ogeda SA, a drug discovery company located in Gosselies, Belgium, and Ogeda has become a wholly owned subsidiary of the company as of CET May 17

May 16 2017

BRIEF- Astellas Pharma to discontinue ASP8273 treatment and close randomization for clinical study protocol 8273-CL-0302

* Says it announced the discontinuation of ASP8273 treatment arm in the the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib

May 10 2017

BRIEF-Astellas Pharma says transfer of 16 Long-Listed Products in Japan to LTL Pharma

* Says Astellas and LTL Pharma Co., Ltd.confirmed the relevant closing conditions are met on April 28 to allow the transfer of the assets related to Astellas’ 16 long-listed products in Japan to LTL Pharma

Apr 28 2017

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31

Apr 26 2017

BRIEF-Astellas Pharma to acquire Ogeda SA

* under agreement, Astellas has agreed to pay up to a total of eur 800 million

Apr 02 2017

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

Mar 21 2017

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

Mar 20 2017

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

Feb 28 2017

BRIEF-Lupin's unit Kyowa and Astellas enter into agreement

* Says Astellas and Lupin s subsidiary Kyowa enter into an agreement

Feb 27 2017

More From Around the Web

Earnings vs. Estimates